IDEAL MAILING LIST
Sign up for information on the next Ideal Experience click here
Here you will have the opportunity to register for a live, interactive Peer-to-Peer (P2P) Teaching Rounds Update with one of the facilitators listed below. During the P2P Teaching Rounds you will discuss a challenging case with a live simulated patient and your facilitator.
| Program Overview | Faculty | Accreditation | Download Meeting Materials |
Led by an expert facilitator, your input and comments will be encouraged throughout this one-hour session. During the session, your group will:
- Discuss recent updates in the management of stroke in patients with atrial fibrillation
- Confer with an expert and your colleagues regarding challenging patient cases
- Explore various perspectives in care delivery and address barriers to positive outcomes
- Engage in active discussion and Q&A with the expert facilitator and the group of your peers
Please RSVP early as each session will be limited to a maximum of 10 participants. The activity is dedicated to enhance your knowledge and skills regarding the prevention and treatment of thromboembolic events in patients at risk and facilitate a positive unique environment for interactive learning that encourages improved patient outcomes.
At the conclusion of this activity, participants should be able to:
- Describe practical appropriate risk stratification strategies for selection of antithrombotic therapy in patients with AF and how to handle the patient with low to moderate risk.
- Communicate with patients the risk and benefits of pharmacological therapy to prevent thromboembolic events in patients with atrial fibrillation.
- Discuss discrepancies in current clinical guidelines for thromboprophylaxis in atrial fibrillation in the context of clinical decision-making.
- Explain the available and emerging therapeutic interventions in terms of prevention of thromboembolic events and risk of major bleeding events.
This activity has been developed to meet the educational needs of physicians, and other healthcare professionals who are involved in the care of patients at risk for thromboembolic events.
Jonathan Halperin, MD, Course Director
Professor of Medicine
Mount Sinai School of Medicine
New York, New York
Elizabeth B. Rothlauf, RN, MS, NPThe Cardiovascular Institute
Mount Sinai Medical Center
New York, New York
Robert L. Talbert, PharmD, FCCP, BCPS Professor of Pharmacy
College of Pharmacy – University of Texas at Austin
Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas
All faculty participating in CME/CE activities sponsored by The American Heart Association will disclose to the audience: (1) significant financial relationships with the manufacturer(s) of products from the commercial supporter(s) and/or the manufacturer(s) of products or devices discussed in their presentation and (2) unlabeled/unapproved uses of drugs or devices discussed in their presentation. Such disclosures will be made in writing in the course presentation materials.
Continuing Medical Education Accreditation – Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Heart Association and Educational Awareness Solutions®.
The American Heart Association is accredited by the ACCME to provide continuing medical education for physicians.
The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Education Accreditation – Nurses
The American Heart Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
The maximum number of hours awarded for this CE activity is 1.00 contact hours.
Accredited status does not imply endorsement by the American Heart Association or the American Nurses Credentialing Center of any commercial products displayed in conjunction with an activity.Continuing Education Accreditation – Pharmacists
The American Heart Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Credit: 1.00 Contact Hours or 0.100 CEUs. Universal Program Number: 0256-9999-11-649-L01-P.
(1) Register for one live telephonic teaching rounds; (2) Participate in the Teaching Rounds; (3) Complete the activity evaluation survey online and claim and print your CME/CE certificate.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Jonathan Halperin, MD, Chair
Consultant/Advisory Board: Astellas Pharma, US., Bayer Health Care, Biotronik, Inc., Boehringer Ingelheim, Bristol Myers-Squibb, Daiichi Sankyo Pharma, Johnson & Johnson, Pfizer, Inc., Protola Pharmaceuticals, Sanofi-Aventis
Honoraria: Boehringer Ingelheim, Pfizer, Inc., Sanofi-Aventis
Elizabeth B. Rothlauf, MS, RN, NP: Nothing to disclose
Robert L. Talbert, PharmD, FCCP, BCPS: Nothing to disclose
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
| Name of Planner or Manager | Reported Financial Relationship |
| Luciano Acevedo – EAS | Nothing to disclose |
| Elizabeth Aven – AHA | Nothing to disclose |
| Heather Haley – EAS | Nothing to disclose |
| James Miller – EAS | Nothing to disclose |
| Pearl Schwartz - EAS | Nothing to disclose |
There is no fee for CME/CE credits for this activity.
This activity is jointly sponsored by the American Heart Association and Educational Awareness Solutions™
This activity is supported by educational grants from Boehringer Ingelheim, Ortho-McNeil, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC, and Bristol-Myers Squibb and Pfizer, Inc.
